Primary progressive multiple sclerosis
TGTXTG TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Azercabtagene zapreleucel (azer-cel) in Primary progressive multiple sclerosis. The expected timing is based on the latest available company guidance and may change.
5/5/25- Enrollment ongoing. 11/03/25:- Enrollment continues in the ongoing Ph1 trial of azer-cel in progressive multiple sclerosis; no efficacy data or timing for the initial data readout was provided. 02/26/26:- Enrollment continues in Ph1 progressive MS trial; preliminary azer-cel data expected in H2 2026. 05/06/26:- Company reiterates ongoing Ph1 enrollment in progressive MS and plans preliminary azer-cel data in H2 2026. 08/03/26:- Preliminary Ph1 progressive MS data reiterated for H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.